SIREN : 324240605
VETO-PHARMA is a French company founded 44 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in PALAISEAU (91120), this company of category ETI shows in 2025 a revenue of 23.5 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 23 488 647 € | 23 035 354 € | 25 579 630 € | 22 830 526 € | 21 760 101 € | 24 134 598 € | 1 952 188 € | 1 306 128 € | 1 925 488 € |
| Net income | 4 895 716 € | 4 702 298 € | 6 291 594 € | 5 135 220 € | 2 311 045 € | 14 587 303 € | 8 298 194 € | -70 329 € | 889 314 € |
| EBITDA | 7 973 417 € | 7 734 340 € | 10 098 993 € | 8 662 389 € | 6 934 757 € | 6 008 461 € | 376 362 € | -301 939 € | -488 135 € |
| Net margin | 20.8% | 20.4% | 24.6% | 22.5% | 10.6% | 60.4% | 425.1% | -5.4% | 46.2% |
In 2025, VETO-PHARMA achieves revenue of 23.5 M€. Over the period 2016-2025, the company shows strong growth with a CAGR (compound annual growth rate) of +32.0%. Vs 2024: +2%. After deducting consumption (4.9 M€), gross margin stands at 18.5 M€, i.e. a rate of 79%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches 8.0 M€, representing 33.9% of revenue. This high EBITDA margin provides strong self-financing capacity and resilience to uncertainties. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 4.9 M€, i.e. 20.8% of revenue. This profit can be retained or distributed to shareholders.
23 488 647 €
18 549 116 €
7 973 417 €
5 326 838 €
4 895 716 €
33.9%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 90%. This high autonomy means the company finances most of its assets through equity, a sign of strength. Cash flow represents 31.6% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
0.0%
90.209%
31.634%
0.0
30.2%
In 2025, the debt ratio of VETO-PHARMA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2025, the financial autonomy of VETO-PHARMA (90.2%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
In 2025, the repayment capacity of VETO-PHARMA (0.00) ranks below the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. This controlled position reflects prudent management.
The liquidity ratio (= Current assets / Current liabilities) stands at 916.53. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months. The interest coverage ratio (= EBIT / Interest expenses) is 0.0x. Danger: operating income does not cover interest charges, unsustainable situation.
916.533
0.015
In 2025, the liquidity ratio of VETO-PHARMA (916.53) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2025, the interest coverage of VETO-PHARMA (0.0x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 79 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 101 days. Favorable situation: supplier credit is longer than customer credit by 22 days. Inventory turnover is 49 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 565 days of revenue, i.e. 36.9 M€ to permanently finance. Over 2016-2025, WCR increased by +1409%, requiring additional financing.
36 893 148 €
79 j
101 j
49 j
565 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 976 789€ to 3 002 269€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare VETO-PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of VETO-PHARMA in 2025 is 23.5 M€.
Yes, VETO-PHARMA generated a net profit of 4.9 M€ in 2025.
The headquarters of VETO-PHARMA is located in PALAISEAU (91120), in the department Essonne.
The tax return of VETO-PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
VETO-PHARMA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.